1 Min Read
March 17 (Reuters) - Amgen Inc said on Monday its experimental new type of cholesterol fighter met the primary goal of a late-stage trial by significantly cutting "bad" LDL cholesterol among patients with a genetic tendency towards very high levels of the artery clogging fat.
Amgen said patients given its injectable drug evolocumab once a month on top of standard daily statin treatments showed "clinically meaningful" improvement compared to statins alone after 12 weeks of treatment.
Evolocumab works by blocking PCSK9, a naturally occurring protein that keeps LDL levels elevated in the bloodstream. Other drugmakers, including Pfizer Inc and a partnership between Regeneron Inc and Sanofi, are racing with Amgen to complete trials of potentially lucrative anti-PCSK9 antibodies.